- Home
- PRTA vs BRW Comparison
PRTA vs BRW Comparison
Compare PRTA & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- BRW
- Stock Information
- Founded
- PRTA 2012
- BRW 1987
- Country
- PRTA Ireland
- BRW United States
- Employees
- PRTA N/A
- BRW N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- BRW Trusts Except Educational Religious and Charitable
- Sector
- PRTA Health Care
- BRW Finance
- Exchange
- PRTA Nasdaq
- BRW Nasdaq
- Market Cap
- PRTA 472.1M
- BRW 355.1M
- IPO Year
- PRTA N/A
- BRW N/A
- Fundamental
- Price
- PRTA $8.20
- BRW $8.31
- Analyst Decision
- PRTA Buy
- BRW
- Analyst Count
- PRTA 10
- BRW 0
- Target Price
- PRTA $14.86
- BRW N/A
- AVG Volume (30 Days)
- PRTA 1.2M
- BRW 222.1K
- Earning Date
- PRTA 08-04-2025
- BRW 01-01-0001
- Dividend Yield
- PRTA N/A
- BRW 15.59%
- EPS Growth
- PRTA N/A
- BRW N/A
- EPS
- PRTA N/A
- BRW N/A
- Revenue
- PRTA $10,341,000.00
- BRW N/A
- Revenue This Year
- PRTA N/A
- BRW N/A
- Revenue Next Year
- PRTA $389.77
- BRW N/A
- P/E Ratio
- PRTA N/A
- BRW N/A
- Revenue Growth
- PRTA N/A
- BRW N/A
- 52 Week Low
- PRTA $4.32
- BRW $7.15
- 52 Week High
- PRTA $22.83
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- PRTA 58.73
- BRW 50.04
- Support Level
- PRTA $8.05
- BRW $8.24
- Resistance Level
- PRTA $8.73
- BRW $8.46
- Average True Range (ATR)
- PRTA 0.38
- BRW 0.08
- MACD
- PRTA -0.05
- BRW -0.01
- Stochastic Oscillator
- PRTA 47.62
- BRW 31.82
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.